2020
HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
Zhao J, Krishnamurti U, Zhang C, Meisel J, Wei Z, Suo A, Aneja R, Li Z, Li X. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer. Pathology - Research And Practice 2020, 216: 153155. PMID: 32871536, DOI: 10.1016/j.prp.2020.153155.Peer-Reviewed Original ResearchConceptsHigh HER2/CEP17 ratioHER2/CEP17 ratioTumor responseBreast cancer casesNeoadjuvant HER2CEP17 ratioNeoadjuvant chemotherapyIHC 3Breast cancerCancer casesRCB II/IIIHER2-positive breast cancerHER2 IHC 3Complete pathologic responseResidual cancer burdenSmaller tumor sizePositive breast cancerLow nuclear gradeHER2 copy numberHigh Ki67Pathologic responseCancer burdenExcisional specimensPositive cancersTumor size
2016
CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition
Kapur N, Mir H, Clark III C, Krishnamurti U, Beech D, Lillard J, Singh S. CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition. British Journal Of Cancer 2016, 114: 1343-1351. PMID: 27149649, PMCID: PMC4984452, DOI: 10.1038/bjc.2016.113.Peer-Reviewed Original ResearchConceptsColon cancerNodal statusCCR6 expressionTherapeutic optionsEMT markersExpression of CCR6Node-positive casesTNM staging systemUndefined molecular mechanismsPotential therapeutic targetNormal adjacent tissuesTissues/cellsMolecular mechanismsIdentification of markersAdjuvant chemotherapyAdvanced diseaseMolecular pathwaysDistant metastasisN-cadherinClinical associationsStaging systemMetastatic casesInvasive potentialΒ-cateninCancer cases